The University of Hong Kong

Other

Versitech, Inc.

City University of Hong Kong

The Hong Kong Polytechnic University

Goldporp Pharma Limited

Laboratory for Synthetic Chemistry and Chemical Biology Limited

Hong Kong Quantum Ai Lab Limited

Chi-Ming Che

Wei Lu

Michael Chi-Wang Chan

Iona Hiu Tung Sham

Siu-Chung Chan

Jun Yang

Kwok-Fai So

Kwok-yin Wong

Man-Kin Wong

Raymond Wai-Yin Sun

Yun Wah Lam

Man-Ho So

Wing-Yiu Yu

Wai Lun Man

Chi-Ming Ho

Wen Xiu Ni

Jiang-Lin Liang

Sze-Chit Yu

Zhike He

Gang Cheng

Chun-Nam Lok

Wai-Ping Lee

Lai-King Sy

Tingjie You

Ella Lai-Ming Wong

Tai Chu Lau

Paul Michel Georges Vanhoutte

Kar-Wai Lo

Compositions and methods for reducing, or inhibiting bone loss in a subject in need thereof have been developed. Pharmaceutical compositions including one or more osteogenic compounds, or functional derivatives thereof, in an effective amount to reduce, or inhibit bone loss, or promote bone formation, preferably via stimulation of osteoblast differentiation, are provided. The compositions are particularly suited for treating bone loss associated with osteoporosis. Methods for treating, or preventing bone loss using the composition, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents, or procedures, are described.

Osteogenic agents and uses thereof

Described herein is an iron(II)-phthalocyanine catalyzed C—H bond amination of alkyl azides. The catalyst is effective to produce intramolecular amination of saturated C—H bonds in moderate to excellent yields and the methods are tolerant of a wide scope of substrates. The methods described are useful for the synthesis of natural products derivatives and for the late-stage functionalization of pharmaceuticals.

Methods of iron catalyzed C-H bond amination

Gold(III) emitters showing high emission quantum efficiency and stable in thermal deposition process are described. High performance OLEDs can be fabricated from these emitters.

Gold complexes for OLED applications

Solid-supported gold nanoparticles for use as a catalyst for the synthesis of quinolines from anilines and aldehydes using oxygen as an oxidant are provided. Also provided are a method for the preparation of SiO-supported gold nanoparticles by in situ deposition of gold nanoparticles to silica gel and a method for synthesizing quinolines from anilines and aldehydes using oxygen as an oxidant.

Solid supported gold nanoparticles, methods of use thereof, and methods for making same

The invention relates to nitridoosmium complexes and methods of using these compounds as treatments for cancer.

Nitridoosmium(VI) complexes for treatment of cancer

Highly fluorescent metallo-supramolecules based on terpyridine-based monomers and transition metals have been obtained. These robust supramolecules provide high quantum yields with emissions from violet to blue, green or yellow color. They have emerged as promising emitters for polymeric light-emitting diodes (PLEDs) due to desirable properties such as high luminance, high purity, low cost, and good thermal stabilities. The supramolecule has molecular structure represented by the formula wherein M represents Group IB, IIB VIIA, VIIIA or lanthanide metals; R is independently in each occurrence and is selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, aryl, substituted aryl, or recognized donor and acceptor groups; X is independently in each occurrence and is nitrogen or carbon atom; R is selected from alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, alkyl ketone, aryl ketone, heteroaryl ketone, alkylester, arylester, heteroarylester, alkylamide, arylamide, heteroarylamide, alkylthio, arylthio, fluoroalkyl, fluoroaryl, amine, imide, carboxylate, sulfonyl, alkyleneoxy, polyalkyleneoxy, or combination thereof; n is an integer of 1 to 100,000; Z is a counter ion and is selected from the group of acetate, acetylacetonate, cyclohexanebutyrate, ethylhexanoate, halide, hexafluorophosphate, hexafluoroacetylacetonate, nitrate, perchlorate, phosphate, sulfate, tetrafluoroborate or fluoromethanesulfonate; y is an integer of 0 to 4.

Electroluminescent metallo-supramolecules with terpyridine-based groups

Disclosed herein are novel light-emitting materials of Formula I and II below. These new complexes are synthesized and found to be sufficiently stable to allow sublimation and vacuum deposition. These new emitters are electrophosphorescent and can be used in organic light-emitting devices (OLEDs) for device elements capable of emitting light of color ranging from orange to red with high-efficiency and high-brightness.  wherein E=Group 16 elements (including sulphur); M=Group 10 metal (including platinum); R-Rare each independently selected from the group consisting of hydrogen; halogen; alkyl; substituted alkyl; aryl; substituted aryl, with substituents selected from the group consisting of halogen, lower alkyl and recognized donor and acceptor groups. Rcan also be selected from (C&#x2261;C)R, where (C&#x2261;C) represents a carbon-carbon triple bond (acetylide group), n is selected from 1 to 10, and Ris selected from alkyl, aryl, substituted aryl, and tri(alkyl)silyl.

Organometallic light-emitting material

Disclosed are electrophosphorescent organic metal complexes with formula (I) or (II), of either geometrical isomers, comprising two bidentate NN-type ligandsor a tetradentate NNNN-type ligand, and a transition metal. These electrophosphorescent materials are valuable to the application in organic light-emitting devices (OLEDs), including red-, orange-, or yellow-light OLEDs.

Organic light-emitting devices

The present invention relates to a pharmaceutical composition comprising one or more of the following ruthenium oxalato compounds I, II, III and IV as an active ingredient. The pharmaceutical composition can be used for the treatment of viral-infected patients or prophylactic treatment of patients at risk from viral infection. 

Pharmaceutical composition having a ruthenium oxalato compound and method of using the same

Disclosed herein are novel light-emitting materials of Formula I and II below. These new complexes are synthesized and found to be sufficiently stable to allow sublimation and vacuum deposition. These new emitters are electrophosphorescent and can be used in organic light-emitting devices (OLEDs) for device elements capable of emitting light of color ranging from orange to red with high-efficiency and high-brightness. 

Aldehydes were obtained in excellent yields from ruthenium-porphyrin-catalyzed oxidation of various terminal alkenes with 2,6-dichloropyridine N-oxide under mild conditions. The aldehydes generated from these ruthenium-catalyzed alkene oxidation reactions can be used in-situ for olefination reactions with ethyl diazoacetate in the presence of PPh, leading to one-pot diazoacetate olefination starting from alkenes.

Method for conversion of terminal alkenes to aldehydes using ruthenium (IV) porphyrin catalysts

Diastereoselective epoxidation of allylically substituted alkenes using metalloporphyrins as catalyst provides high trans-selectivities (i.e., trans-:cis-epoxide ratio). A diversity of cycloalkenes bearing different allylic substituents are shown to be efficiently epoxidized to afford the corresponding trans-epoxides with excellent trans-selectivities (up to &#x3e;98%) and good yields (up to 99%). Acyclic allylic alkenes bearing different allylic substituents are efficiently epoxidized to afford the corresponding erythro-epoxides with good erythro-selectivities. The metalloporphyrin-catalyzed reactions exhibit up to 20 times higher trans-selectivities than the conventional method using m-chloroperoxybenzoic acid as oxidant. 

Diastereoselective epoxidation of allylically substituted alkenes using metalloporphyrin catalysts

This invention provides a method for treating an eye disease in a patient comprising: providing a photosensitive prodrug that releases upon exposure to light an active ingredient to treat the eye disease; administering the prodrug in a pharmaceutically accepted vehicle to the subject, and exposing the eye of the subject to an external light source to cause the prodrug to release the active ingredient. This invention also provides a composition for the treatment of glaucoma, comprising a compound containing a lithium ion-chelated in a crown ether- or aza-crown ether-containing chromene or diazene derivative and a pharmaceutically acceptable carrier.

Diazene-bridge crown ether lithium compounds and methods for their use

The present invention relates to the use of nanosized metal particles (e.g., ruthenium) grafted on inert solid support for oxidation of alkenes. The supported metal catalyst can effect cis-dihydroxylation and oxidative cleavage of alkenes to give the respective cis-diols and carbonyl products.

Supported ruthenium nanoparticle catalyst for cis -dihydroxylation and oxidative cleavage of alkenes

Disclosed are emissive materials of formula (I) or (II), comprising two bidentate NO-type ligands, or a tetradentate NOON-type ligand, and a transition metal. The emissive materials are useful as electrophosphorescent emitters in organic light-emitting devices. Also disclosed are methods for preparing organic light-emitting diodes comprising these emissive materials, and the use of such diodes as white and yellow organic light-emitting devices. 

Growing community of inventors

Hong Kong, China

Chi-Ming Che